Compare STBA & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STBA | ARDX |
|---|---|---|
| Founded | 1902 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1995 | 2014 |
| Metric | STBA | ARDX |
|---|---|---|
| Price | $43.12 | $5.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $43.00 | $15.14 |
| AVG Volume (30 Days) | 162.1K | ★ 3.0M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | ★ 2.35 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | $10.20 | $37.75 |
| Revenue Next Year | $4.14 | $34.24 |
| P/E Ratio | $12.46 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.01 | $3.50 |
| 52 Week High | $44.91 | $8.40 |
| Indicator | STBA | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 45.34 |
| Support Level | $42.08 | $5.49 |
| Resistance Level | $43.42 | $6.23 |
| Average True Range (ATR) | 0.91 | 0.24 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 29.04 | 25.31 |
S&T Bancorp Inc is a bank holding company. The company operates in five markets including Western Pennsylvania, Eastern Pennsylvania, Northeast Ohio, Central Ohio and Upstate New York. The company provides financial services with retail and commercial banking products, cash management services, trust and brokerage services. It operates only in one segment which is Community Banking. The company earns revenue from interest on loans and securities and fees charged for financial services provided to its customers.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.